Key facts
- Notable investors include Addor Capital, Puhua Capital, Co-Stone Capital, CDH Investments, China Capital Management — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Kangweijian Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Kangweijian Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kangweijian Biotechnology
Developer of ascorbyl palmitate designed for animal nutrition and pharmaceutical ingredients. The company integrates research and development, manufacturing, and sales, focusing on animal nutrition, pharmaceutical ingredients, and cosmetic ingredients, providing environmentally friendly production, helping customers benefit from reliable, compliant, and effective products, enabling improved health, nutrition, and well-being.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2020
- Ownership
- Privately Held (backing)
Kangweijian Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Kangweijian Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Kangweijian Biotechnology in its N-PORT filings yet. We sweep new filings monthly.